A Bloomington surgeon alleging Indiana University Health violated federal antitrust laws by acquiring local competitors has convinced the 7th Circuit Court of Appeals to reinstate his complaint.
Like a kite that has caught a stiff breeze, Eli Lilly and Co. stock is having the ride of its life. Shares in the Indianapolis-based drugmaker have soared 41% in the past 52 weeks, to about $331 each.
The West Lafayette-based pharmaceutical testing company has seen its stock price soar—and later plunge—following its announcement last fall that it planned to acquire Indianapolis-based Envigo RMS LLC, which breeds and sells animals used in lab testing.
Just five years ago this summer, officials from Ascension St. Vincent opened the first of five tiny hospitals in the Indianapolis area, touting them as a new model of ease and comfort for patients.
A series of federal and state actions are putting the $400 billion PBM industry under a spotlight.
BiomEdit, one of Indiana’s newest life-science companies, said Monday it will locate its headquarters in Fishers, but hinted it could eventually move to the new $100 million Elanco Animal Health headquarters campus now under construction in Indianapolis.
This is the third acquisition announced this year for Indianapolis-based Greenlight Guru, which offers a platform to help medical device makers with regulatory requirements.
Several analysts said Elanco faces a bright future, implying that the market might be overreacting to the lowered revenue and profit guidance.
It should come as no surprise that pandemic-related supply chain challenges have also had a major impact on the life sciences industry.
The pharmaceutical giant is turning heads with an experimental medicine it claims can help obese patients shed nearly a quarter of their body weight and manage diabetes.
Indiana University Health lost $29.8 million, and Community Health lost $28.5 million during the quarter, as both systems postponed surgeries to deal with the rising number of COVID-19 cases.
Eli Lilly and Co. posted profit of $1.9 billion in the first quarter, up 40%, on higher sales of COVID-19 antibodies and other key products for diabetes, cancer and arthritis.
The funding included 39 Indiana life-science companies raising $433.5 million last year in venture capital, an increase of almost $200 million compared to 2020, according to a report issued by BioCrossroads.
The imaging agent is the six-year-old company’s first commercial launch, following millions of dollars’ worth of research and clinical tests. It was approved by the U.S. Food and Drug Administration in December.
Acacia Pharma Group employees are waiting to see what will happen to their jobs and whether the company will remain in Indianapolis in any form, now that it is being acquired by New Jersey-based specialty drugmaker Eagle Pharmaceuticals Inc. for $103.9 million.
The push by Eli Lilly and Co. will come despite an unfavorable ruling last week from Medicare that sharply restricts reimbursements for a drug in the same class.
Brooke Beier, senior vice president of commercialization at the Purdue Research Foundation, said FDA approval of the therapy is one of the most meaningful approvals ever for a Purdue-related innovation.
Rural hospitals have long struggled to stay afloat. But now, the sector is facing a wave of closings under additional financial pressures, some caused by the pandemic that has strained resources.
The West Lafayette life sciences company was awarded the $974,349 grant to further the development of a core technology known as Collymer. It can be used to create implantable materials for tissue restoration and reconstruction needs such as breast tissue, skeletal muscle, cartilage and more.
The medical-device maker is vigorously defending itself against a mountain of lawsuits that claim its inferior vena cava (IVC) filters, designed to catch blood clots, are unsafe.
